Given that VEGF and FGFR expression is correlated with angiogenesis, proliferation, and metastatic potential of tumor cells [23,26], inhibitors of the FGFR/VEGF receptor (VEGFR) signaling pathways may be an effective novel therapeutic intervention for HCC. Here, KDR is linked to hepatocellular carcinoma.